Titre : Endotoxines

Endotoxines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Leukocyte L1 Antigen Complex
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Endotoxines : Questions médicales les plus fréquentes", "headline": "Endotoxines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Endotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-12", "dateModified": "2025-05-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Endotoxines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Toxines bactériennes", "url": "https://questionsmedicales.fr/mesh/D001427", "about": { "@type": "MedicalCondition", "name": "Toxines bactériennes", "code": { "@type": "MedicalCode", "code": "D001427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipopolysaccharides", "alternateName": "Lipopolysaccharides", "url": "https://questionsmedicales.fr/mesh/D008070", "about": { "@type": "MedicalCondition", "name": "Lipopolysaccharides", "code": { "@type": "MedicalCode", "code": "D008070", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Lipide A", "alternateName": "Lipid A", "url": "https://questionsmedicales.fr/mesh/D008050", "about": { "@type": "MedicalCondition", "name": "Lipide A", "code": { "@type": "MedicalCode", "code": "D008050", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.500" } } }, { "@type": "MedicalWebPage", "name": "Antigènes O", "alternateName": "O Antigens", "url": "https://questionsmedicales.fr/mesh/D019081", "about": { "@type": "MedicalCondition", "name": "Antigènes O", "code": { "@type": "MedicalCode", "code": "D019081", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.946.123.329.500.600" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Endotoxines", "alternateName": "Endotoxins", "code": { "@type": "MedicalCode", "code": "D004731", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johannes Reich", "url": "https://questionsmedicales.fr/author/Johannes%20Reich", "affiliation": { "@type": "Organization", "name": "Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Stanberger See, Germany. j.reich@microcoat.de." } }, { "@type": "Person", "name": "Guy C Brown", "url": "https://questionsmedicales.fr/author/Guy%20C%20Brown", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK. gcb3@cam.ac.uk." } }, { "@type": "Person", "name": "John A Kellum", "url": "https://questionsmedicales.fr/author/John%20A%20Kellum", "affiliation": { "@type": "Organization", "name": "Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA." } }, { "@type": "Person", "name": "Gary Hannon", "url": "https://questionsmedicales.fr/author/Gary%20Hannon", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } }, { "@type": "Person", "name": "Adriele Prina-Mello", "url": "https://questionsmedicales.fr/author/Adriele%20Prina-Mello", "affiliation": { "@type": "Organization", "name": "Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Dublin, Ireland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Dendritic cells steering antigen and leukocyte traffic in lymph nodes.", "datePublished": "2024-07-12", "url": "https://questionsmedicales.fr/article/38997244", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/1873-3468.14982" } }, { "@type": "ScholarlyArticle", "name": "Advances in desensitization for human leukocyte antigen incompatible kidney transplantation.", "datePublished": "2023-12-14", "url": "https://questionsmedicales.fr/article/38088373", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MOT.0000000000001131" } }, { "@type": "ScholarlyArticle", "name": "Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.", "datePublished": "2023-10-02", "url": "https://questionsmedicales.fr/article/37883087", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2023.38612" } }, { "@type": "ScholarlyArticle", "name": "Human Leukocyte Antigen-DQ Genotyping in Pediatric Celiac Disease.", "datePublished": "2023-01-10", "url": "https://questionsmedicales.fr/article/36816433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5223/pghn.2023.26.1.50" } }, { "@type": "ScholarlyArticle", "name": "How to measure human leukocyte antigen-specific B cells.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37678170", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MOT.0000000000001097" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Toxines biologiques", "item": "https://questionsmedicales.fr/mesh/D014118" }, { "@type": "ListItem", "position": 4, "name": "Toxines bactériennes", "item": "https://questionsmedicales.fr/mesh/D001427" }, { "@type": "ListItem", "position": 5, "name": "Endotoxines", "item": "https://questionsmedicales.fr/mesh/D004731" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Endotoxines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Endotoxines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Endotoxines", "description": "Comment diagnostiquer une intoxication par endotoxines ?\nQuels tests sont utilisés pour détecter les endotoxines ?\nQuels signes cliniques indiquent une exposition aux endotoxines ?\nLes endotoxines peuvent-elles être détectées dans le sang ?\nQuel rôle joue la culture bactérienne dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Endotoxines", "description": "Quels sont les symptômes d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles le système immunitaire ?\nLes endotoxines causent-elles des douleurs ?\nQuels signes indiquent un choc septique dû aux endotoxines ?\nLes symptômes varient-ils selon l'exposition ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Endotoxines", "description": "Comment prévenir l'exposition aux endotoxines ?\nLes vaccins peuvent-ils prévenir les infections à endotoxines ?\nQuelles mesures de sécurité en laboratoire sont nécessaires ?\nLes antibiotiques préventifs sont-ils efficaces ?\nComment réduire le risque d'infections nosocomiales ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Endotoxines", "description": "Quel est le traitement principal pour une intoxication par endotoxines ?\nLes corticostéroïdes sont-ils efficaces contre les endotoxines ?\nComment traiter le choc septique causé par des endotoxines ?\nLes antidotes existent-ils pour les endotoxines ?\nQuelle est l'importance de la prise en charge précoce ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Endotoxines", "description": "Quelles sont les complications possibles d'une intoxication par endotoxines ?\nComment les endotoxines affectent-elles les organes ?\nLe syndrome de détresse respiratoire est-il lié aux endotoxines ?\nLes endotoxines peuvent-elles causer des dommages neurologiques ?\nQuel est le pronostic après une exposition aux endotoxines ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Endotoxines", "description": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?\nLes infections bactériennes augmentent-elles le risque d'endotoxines ?\nLes interventions chirurgicales augmentent-elles le risque ?\nLe diabète est-il un facteur de risque pour les endotoxines ?\nLes conditions de vie insalubres augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D004731?mesh_terms=Leukocyte+L1+Antigen+Complex&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication par endotoxines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, cultures et évaluation clinique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les endotoxines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Le test de limule et les tests ELISA sont couramment utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une exposition aux endotoxines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, hypotension et tachycardie sont des signes fréquents." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles être détectées dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent détecter les endotoxines dans le sang." } }, { "@type": "Question", "name": "Quel rôle joue la culture bactérienne dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'identifier la source bactérienne des endotoxines." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication par endotoxines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, frissons, douleurs abdominales et confusion." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles provoquent une réponse inflammatoire excessive, pouvant mener à un choc." } }, { "@type": "Question", "name": "Les endotoxines causent-elles des douleurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des douleurs abdominales et musculaires." } }, { "@type": "Question", "name": "Quels signes indiquent un choc septique dû aux endotoxines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Hypotension, tachycardie, confusion et peau froide sont des signes clés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'exposition ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité des symptômes dépend de la dose et de la durée d'exposition." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux endotoxines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les environnements contaminés et respecter les protocoles d'hygiène." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les infections à endotoxines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre les endotoxines, mais contre certaines bactéries." } }, { "@type": "Question", "name": "Quelles mesures de sécurité en laboratoire sont nécessaires ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle et des procédures de désinfection." } }, { "@type": "Question", "name": "Les antibiotiques préventifs sont-ils efficaces ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être utilisés dans certains cas à risque, mais pas systématiquement." } }, { "@type": "Question", "name": "Comment réduire le risque d'infections nosocomiales ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Améliorer l'hygiène hospitalière et le contrôle des infections est essentiel." } }, { "@type": "Question", "name": "Quel est le traitement principal pour une intoxication par endotoxines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des antibiotiques et des soins de soutien pour stabiliser le patient." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces contre les endotoxines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'inflammation, mais leur utilisation est controversée." } }, { "@type": "Question", "name": "Comment traiter le choc septique causé par des endotoxines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement nécessite des fluides intraveineux et des vasopresseurs." } }, { "@type": "Question", "name": "Les antidotes existent-ils pour les endotoxines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique." } }, { "@type": "Question", "name": "Quelle est l'importance de la prise en charge précoce ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une prise en charge rapide améliore les chances de survie et réduit les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles d'une intoxication par endotoxines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le choc septique, l'insuffisance organique et la mort." } }, { "@type": "Question", "name": "Comment les endotoxines affectent-elles les organes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer une défaillance multi-organique en raison de l'inflammation." } }, { "@type": "Question", "name": "Le syndrome de détresse respiratoire est-il lié aux endotoxines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inflammation pulmonaire peut entraîner un syndrome de détresse respiratoire." } }, { "@type": "Question", "name": "Les endotoxines peuvent-elles causer des dommages neurologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des troubles neurologiques en raison de l'inflammation systémique." } }, { "@type": "Question", "name": "Quel est le pronostic après une exposition aux endotoxines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le pronostic dépend de la rapidité du traitement et de la gravité de l'exposition." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'intoxication par endotoxines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés, les personnes âgées et les hospitalisés sont à risque." } }, { "@type": "Question", "name": "Les infections bactériennes augmentent-elles le risque d'endotoxines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections par des bactéries Gram-négatives sont un facteur de risque majeur." } }, { "@type": "Question", "name": "Les interventions chirurgicales augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les interventions chirurgicales peuvent exposer à des endotoxines, surtout en cas d'infection." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour les endotoxines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les conditions de vie insalubres augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles favorisent la prolifération bactérienne et l'exposition aux endotoxines." } } ] } ] }

Sources (10000 au total)

Advances in desensitization for human leukocyte antigen incompatible kidney transplantation.

Human leukocyte antigen (HLA) sensitization is a major barrier to kidney transplantation induced by exposure to alloantigens through pregnancy, blood product exposure and previous transplantations. De... Newer desensitization strategies such as imlifidase [immunoglobulin G (IgG) endopeptidase] rapidly inactivates IgG molecules and creates an "antibody-free zone", representing an important advancement ... Use of these agents alone or in combination will likely improve the efficacy and durability of desensitization therapies, improving access to kidney transplantation for immunologically disadvantaged p...

Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.

The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likel... To determine whether racial and ethnic inequities were present with regard to trial eligibility in trials investigating a therapeutic restricted to patients with specific HLA subtypes.... This cross-sectional study included all clinical trials registered in ClinicalTrials.gov through March 18, 2022, that investigated an interventional study of a therapeutic strategy and restricted part... The type of therapeutics used in trials, the condition under study, the HLA subtypes used, and the likelihood of being enrolled in such a trial according to race and ethnicity.... Of 2135 trials identified, 263 met inclusion criteria. Overall, the estimated likelihood of being eligible for an HLA-based trial was 50.3%. Individuals of African American descent had the lowest like... The findings of this cross-sectional study suggest that enrollment restrictions for clinical trials investigating novel HLA therapeutics may be associated with racial and ethnic inequities with regard...

Human Leukocyte Antigen-DQ Genotyping in Pediatric Celiac Disease.

The purpose of this study was to determine the pattern of human leukocyte antigen (HLA)-DQ genotype in children diagnosed with celiac disease (CD) (biopsy proven), and to compare this with a control g... This cross-sectional comparative observational study included 26 controls and 52 patients diagnosed with CD who presented at Sir Padampat Mother and Child Health Institute, Jaipur, from May, 2017 to O... HLA DQ2/DQ8 genotypes were significantly more common in CD (present in 100.0% cases) than in controls (23.1%) in Northern India (Rajasthan). When HLA DQ2.5 and DQ8 were present together, individuals h... HLA DQ2/DQ8 genotypes are strongly associated with pediatric CD patients in northern India. These genotypes and their combinations may be associated with different clinical presentations of CD, and ma...

How to measure human leukocyte antigen-specific B cells.

The implementation of highly sensitive immune assays measuring anti-human leukocyte antigen (HLA) antibodies has modified alloimmune risk stratification and diagnosis of rejection. Nonetheless, anti-H... Functional assays involving ex vivo polyclonal activation of mBC have been refined to allow the detection of HLA-specific mBC capable of producing anti-HLA Abs, using different and complementary detec... Technological refinements have allowed the development of tests detecting HLA-specific mBC. Further evaluation of these assays in clinical trials, both for immune risk stratification and to assess tre...

Heart Transplant Human Leukocyte Antigen Matching in the Modern Era.

Although numerous reports have studied the consequences of human leukocyte antigen (HLA) mismatching in renal transplantation, there are limited and outdated data analyzing this association in thoraci... We performed a retrospective analysis of adult patients after heart transplant by using the United Network for Organ Sharing database from January 2005-July 2021. Total HLA and HLA-A, HLA-B and HLA-DR... A total of 33,060 patients were included in this study. Recipients with a high degree of HLA mismatching had increased incidences of acute organ rejection. There were no significant differences in mor... Our analysis suggests that HLA mismatch is not a significant predictor of survival in the modern era. Overall, the clinical implications of this study provide reassuring data for the continued use of ...

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.

Since the beginning of the anti-COVID-19 vaccination campaign, it has become evident that vaccinated subjects exhibit considerable inter-individual variability in the response to the vaccine that coul... We carried out a genome-wide association study to investigate the genetic determinants of the antibody response to the Pfizer-BioNTech vaccine in an Italian cohort of 1351 subjects recruited in three ... Our study confirms the involvement of the HLA locus and shows significant associations with variants in HLA-A, HLA-DQA1, and HLA-DQB1 genes. In particular, the HLA-A*03:01 allele is the most significa... These results support the hypothesis that HLA genes modulate the response to Pfizer-BioNTech vaccine and highlight the need for genetic studies in diverse populations and for functional studies aimed ...

Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia marked by progressive lung fibrosis and a poor prognosis. Recent studies have highlighted the potential role of infection in the... We performed a meta-analysis of associations of the HLA region with IPF risk in individuals of European ancestry from seven independent case-control studies of IPF (comprising 5159 cases and 27 459 co... The meta-analysis of all seven studies identified four significant independent single nucleotide polymorphisms associated with IPF risk. However, none met the posterior probability for replication cri... Variation in the HLA region was not consistently associated with risk in studies of IPF. However, this does not preclude the possibility that other genomic regions linked to the immune response may be...

Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.

Cancer cells evade recognition by the immune system to survive. Head and neck squamous cell carcinoma (HNSCC) is characterized by high levels of immune infiltration and mutation-associated neoantigens... Cross-sectional integrated clinical and genomic analysis.... Whole-exome sequencing and RNA-sequencing data from 522 tumors profiled in The Cancer Genome Atlas HNSCC cohort were analyzed and integrated with secondary analyses including immune cell deconvolution... HLA LOH was a prevalent event that was identified in 53% of HNSCC tumors; in many cases, more than one class I HLA gene was targeted for LOH. HLA LOH was more common in advanced-stage tumors. Tumors w... HLA LOH is one of the most prevalent genetic alterations in HNSCC, and is associated with a cold immune microenvironment, suggesting that HLA LOH is a means of immune evasion. It may have value as a p... 3 Laryngoscope, 2023....